Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may uncover rare diseases in myeloma patients

NCT ID NCT05992532

Knowledge-focused Sponsor: Fundación Española de Hematología y Hemoterapía Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find out how many people with an enlarged spleen or certain blood disorders (like multiple myeloma) also have Gaucher disease or acid sphingomyelinase deficiency (ASMD). Researchers will use a simple blood spot test to check for these rare conditions. The goal is to improve diagnosis and understand how common these diseases are in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Adult patients of both sexes. * Patients who present signs, assessed instrumentally or with laboratory tests, of unknown splenomegaly, defined as a palpable spleen ≥ 1cm from the costal margin or diagnosed by ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) of the spleen. * Splenectomy patient with no diagnosis of the origin of the splenomegaly of unknown origin. * Patients with thrombocytopenia. In cases where the patient is undergoing treatment for their underlying condition, the thrombocytopenia must have been present prior to the start of the treatment

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients of both sexes. * Patients with splenomegaly (spleen palpable at ≥ 1cm from the costal margin) or splenectomy not related to any specific condition, or patients with thrombocytopenia (with or without splenomegaly). In cases where the patient is undergoing treatment for their underlying condition, the thrombocytopenia must have been present prior to the start of the treatment. * Patient who gives their consent to participate in the study. Exclusion Criteria: * Splenomegaly due to portal hypertension (documented by abdominal ultrasound or other instrumental test) due to liver disease * Hematologic malignancy \[documented by positive physical exam + blood smear or fine needle aspiration (FNA) or bone marrow biopsy\] * Hemolytic anemia and/or thalassemia * Patients who cannot meet the requirements of the protocol due to mental and/or cognitive alterations, uncooperative patients, educational limitations and understanding of written language * Refusal of the patient to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acid sphingomyelinase deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acid sphingomyelinase deficiency Gaucher disease monoclonal gammopathy monoclonal gammopathy of uncertain significance Niemann-Pick disease plasma cell myeloma Splenomegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acid sphingomyelinase deficiency Gaucher disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Asistencial de Ávila

    RECRUITING

    Ávila, Ávila, Spain

  • Complejo Hospitalario Universitario de Orense

    RECRUITING

    Ourense, Orense, Spain

  • Hospital Alcañiz

    RECRUITING

    Alcañiz, Teruel, Spain

  • Hospital Alvaro Cunqueiro

    RECRUITING

    Vigo, Pontevedra, Spain

  • Hospital Arnau de Vilanova

    RECRUITING

    Lleida, Lleida, Spain

  • Hospital Clínico Universitario de Valladolid

    RECRUITING

    Valladolid, Zaragoza, Spain

  • Hospital Fundación Jiménez Díaz

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital Parc Taulí

    RECRUITING

    Sabadell, Barcelona, Spain

  • Hospital Regional Universitario de Málaga

    RECRUITING

    Málaga, Málaga, Spain

  • Hospital San Jorge

    RECRUITING

    Huesca, Huesca, Spain

  • Hospital Son Espases

    RECRUITING

    Palma de Mallorca, Balearic Islands, Spain

  • Hospital Universitario Dr. Josep Trueta

    RECRUITING

    Girona, Girona, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario Torrecárdenas

    RECRUITING

    Almería, Almería, Spain

  • Hospital Universitario Virgen de las Nieves

    RECRUITING

    Granada, Granada, Spain

  • Hospital Universitario de Burgos

    RECRUITING

    Burgos, Burgos, Spain

  • Hospital Universitario de Álava

    RECRUITING

    Vitoria-Gasteiz, Alava, Spain

  • Hospital Universitario y Politécnico La Fe

    RECRUITING

    Valencia, Valencia, Spain

  • Hospital de Jaén

    RECRUITING

    Jaén, Jaén, Spain

  • Hospital de Manises

    RECRUITING

    Valencia, Valencia, Spain

  • Hospital de Valdepeñas

    RECRUITING

    Valdepeñas, Ciudad Real, 28040, Spain

  • Hospital del Bierzo

    RECRUITING

    Ponferrada, León, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.